← Leaderboards
Christy Russell
University Of Southern California
$719,837
Attributed
$719,837
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$719,837 · 5
By mechanism
M01$719,837 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Derek Raghavan$1,863,220
- Heinz Josef Lenz$20,123,312
- Richard James Cote$13,022,506
- John A Zaia$8,207,353
- Dan Douer$1,774,545
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchNeoplasm /Cancer ChemotherapyCombination ChemotherapyBreast NeoplasmsPharmacokineticsCis Platinum CompoundFemaleDrug Screening /EvaluationImmunomodulatorsNeoplasm /Cancer Relapse /RecurrenceCytosine ArabinosideDrug ResistanceGemcitabinePaclitaxelGliomaHydroxyureaImmunocytochemistryOncogenesUridineClinical Trial Phase IDosageNucleoside Analog
Grant awards (17)
Gemcitabine and Cisplatin in Treatment of Breast Cancer$25,675
M01 · FY2004 · RR
SWOG 9149--CISPLATIN PRECEDED BY 12HR INFUSION OF HYDROXY &ARA C IN GLIOMA$0
M01 · FY2002 · RR
VX710 &TAXOL--EFFECT IN WOMEN W/ ADV BREAST CANCER REFRACTORY TO TAXOL$0
M01 · FY2002 · RR
VX710 &TAXOL--EFFECT IN WOMEN W/ ADV BREAST CANCER REFRACTORY TO TAXOL$155,764
M01 · FY2001 · RR
SWOG 9149--CISPLATIN PRECEDED BY 12HR INFUSION OF HYDROXY &ARA C IN GLIOMA$155,764
M01 · FY2001 · RR
SWOG 9149--CISPLATIN PRECEDED BY 12HR INFUSION OF HYDROXY &ARA C IN GLIOMA$0
M01 · FY2001 · RR
VX710 &TAXOL--EFFECT IN WOMEN W/ ADV BREAST CANCER REFRACTORY TO TAXOL$0
M01 · FY2001 · RR
SWOG 9149--CISPLATIN PRECEDED BY 12HR INFUSION OF HYDROXY &ARA C IN GLIOMA$155,764
M01 · FY2000 · RR
VX710 &TAXOL--EFFECT IN WOMEN W/ ADV BREAST CANCER REFRACTORY TO TAXOL$155,764
M01 · FY2000 · RR
VX710 &TAXOL--EFFECT IN WOMEN W/ ADV BREAST CANCER REFRACTORY TO TAXOL$35,553
M01 · FY2000 · RR
SWOG 9149--CISPLATIN PRECEDED BY 12HR INFUSION OF HYDROXY &ARA C IN GLIOMA$35,553
M01 · FY2000 · RR
TRIAL OF 5-FLUORO-2'-DEOXYCYTIDINE W TETRAHYDROURIDINE$0
M01 · FY2000 · RR
TRIAL OF 5-FLUORO-2'-DEOXYCYTIDINE W TETRAHYDROURIDINE$0
M01 · FY2000 · RR
GEMCITABINE AND CISPLATIN IN MINIMALLY PRETREATED BREAST CANCER$0
M01 · FY2000 · RR
GEMCITABINE AND CISPLATIN IN MINIMALLY PRETREATED BREAST CANCER$0
M01 · FY2000 · RR
GEMCITABINE AND CISPLATIN IN HEAVILY PRETREATED BREAST CANCER$0
M01 · FY2000 · RR
GEMCITABINE AND CISPLATIN IN HEAVILY PRETREATED BREAST CANCER$0
M01 · FY2000 · RR